ArticleMolecular biology reports2026
Dnmt3a-mediated abnormal DNA methylation is associated with myelination deficits in offspring of advanced maternal age rats.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAdvanced maternal age (AMA) threatens offspring brain development, yet its neurodevelopment-disrupting mechanisms remain poorly understood. Our prior work has suggested that AMA may impair myelin development in offspring, accompanied by increased Dnmt3a expression and DNA methylation levels in the hippocampus. This study explores whether Dnmt3a mediates myelination defects in offspring of AMA rats.
methodsLentiviral vectors were intracerebroventricularly administered to modulate Dnmt3a expression in AMA offspring after birth. Protein expression was analyzed by western blotting and immunofluorescence at postnatal days (P) 7, 14, and 28. Myelin development was evaluated at P28 using transmission electron microscopy, immunofluorescence, luxol fast blue staining, and glycine silver staining. Cognitive function was assessed using the novel object recognition test from P23 to P24.
resultsAMA offspring exhibited impaired oligodendrocyte precursor cell (OPC) maturation and abnormal myelination during early postnatal brain development. Inhibition of Dnmt3a increased the expression of CNPase, MBP, and Olig2, which are associated with oligodendrocyte lineage maturation and myelination, and alleviated myelin deficits and cognitive impairment. Furthermore, Dnmt3a inhibition reduced 5-methylcytosine levels in PDGFR-α-positive cells and decreased Dnmt3a expression in Olig2-positive cells. In contrast, Dnmt3a overexpression did not significantly alter myelination-related phenotypes.
conclusionIn conclusion, Dnmt3a dysregulation could be associated with altered OPC maturation and myelination in AMA offspring, possibly mediated by epigenetic mechanisms involving Olig2. Dnmt3a downregulation partially restores oligodendrocyte lineage maturation, myelin development, and cognitive function. These findings suggest that Dnmt3a may serve as a potential molecular target for further investigation in the prevention of neurodevelopmental impairments associated with AMA.
Indexed as
Identifiers
42611340What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.